AI Advancements in Antibody-Based Drug Development: From Target to Clinical Candidate

Abstract

Why can we develop a COVID-19 vaccine in under a year, but cancer drugs still take a decade and billions of dollars? This talk takes you through the full journey of antibody-based drug development, from identifying a disease target to having a molecule ready for human trials, and shows how AI is fundamentally reshaping that timeline. We’ll walk through each stage of the pipeline (target identification, antibody discovery, lead optimization, and preclinical development) and explore how tools like AlphaFold, RFdiffusion, and generative protein language models are working alongside traditional lab science to compress years of work into months. You don’t need a biology background, just curiosity about how machines are learning to design molecules that could save lives. You’ll leave understanding what “humanizing an antibody” actually means, why your ML skills might translate surprisingly well to biotech, and where the real bottlenecks in drug discovery still remain.

Key Takeaways

The bottleneck isn’t discovery anymore. AI has compressed antibody discovery and optimization from years to months, but clinical trials (still 3-5 years) remain the rate-limiting step drug development can’t yet shortcut.

AI and lab science are complementary, not competing. The biggest gains come from “lab-in-the-loop” systems where AI proposes designs, wet-lab experiments validate them, and results feed back to improve the model

Structure prediction solved one problem; design is the new frontier. AlphaFold-era tools tell us what a molecule looks like. Generative models (diffusion-based, LLM-based) are now tackling the harder question: what molecule should we build for a given target.

The universal challenge is multi-objective optimization. Every antibody candidate must simultaneously satisfy binding affinity, stability, manufacturability, and safety: optimizing one property often breaks another. AI’s biggest value-add is solving this “whack-a-mole” problem faster than trial-and-error.

Good ML in biotech requires biological context, not just algorithms. The teams getting the most value from AI aren’t the ones with the best models. They’re the ones who understand which stage of the pipeline actually needs help, and where a wrong prediction is costly versus cheap to correct.